WORLD'S LARGEST MARKET RESEARCH RESOURCE — 1,519,265 REPORTS

 
 
• SEARCH FOR A REPORT

Viewing report

Search
Enter keywords, a title or a report id number below.
Advanced

• ORDER BY FAX

Order By Fax

• SELECT SITE CURRENCY

Select a currency for use throughout the site



  • Electronic (PDF) Information Icon
  • Site License Information Icon
  • Enterprisewide Information Icon
Live Chat Live Help Software for Website

Targa Therapeutics Corp. - Product Pipeline Review - H2 2011

Global Markets Direct, December 2011, Pages: 29

Targa Therapeutics Corp. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Targa Therapeutics Corp. - Product Pipeline Review - H2 2011” provides data on the Targa Therapeutics Corp.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Targa Therapeutics Corp.’s corporate website, SEC filings, investor presentations and featured press releases, both from Targa Therapeutics Corp. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Targa Therapeutics Corp. - Brief Targa Therapeutics Corp. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Targa Therapeutics Corp. human therapeutic division.
- Overview o



List of Tables
List of Figures
Targa Therapeutics Corp. Snapshot
Targa Therapeutics Corp. Overview
Key Information
Key Facts
Targa Therapeutics Corp. – Research and Development Overview
Key Therapeutic Areas
Targa Therapeutics Corp. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Targa Therapeutics Corp. – Pipeline Products Glance
Targa Therapeutics Corp. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Targa Therapeutics Corp. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Targa Therapeutics Corp. – Drug Profiles
BreMel/TNF-a
Product Description
Mechanism of Action
R&D Progress
Granzyme B/VEGF
Product Description
Mechanism of Action
R&D Progress
HuM195/rGel
Product Description
Mechanism of Action
R&D Progress
scFvMel/rGel
Product Description
Mechanism of Action
R&D Prog

Customers who bought this item also bought